UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerNeoplasia: the second decade.Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis.Imaging ligand-dependent activation of CXCR7.Methoxyethylamino-numonafide is an efficacious and minimally toxic amonafide derivative in murine models of human cancer.Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression.Naphthalimides induce G(2) arrest through the ATM-activated Chk2-executed pathway in HCT116 cells.The War on Cancer rages on.Synthesis and evaluation of novel amonafide-polyamine conjugates as anticancer agents.Novel naphthalimide polyamine derivatives as potential antitumor agents.Conjugation of substituted naphthalimides to polyamines as cytotoxic agents targeting the Akt/mTOR signal pathway.UNBS5162 inhibits proliferation of human retinoblastoma cells by promoting cell apoptosis.UNBS5162 inhibits the proliferation of human A549 non-small-cell lung cancer cells by promoting apoptosis.UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cellsThe influence of bisnaphthalimidopropyl polyamines on DNA instability and repair in Caco-2 colon epithelial cellsDown-regulation of CXCL 11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition
P2860
Q24628746-629D65DE-5127-481D-8E63-3FD9E929832CQ30484000-B544E07C-9050-41DD-AF03-2FE9ED5B01E5Q33519074-FDCC0C0F-FA67-44F4-8335-31714325FAEFQ34659164-C06072C1-4D2D-49CC-AFD3-7B674B8EFA1BQ34887641-ADC182E5-47C2-4DD1-96F5-FEB1B6D109E1Q36982114-FD56654B-DA25-4694-AFE1-47A56E5550DAQ37165859-0CE46648-C6D7-43DB-A8BF-4C2E276E67E2Q37399288-E6CC1936-CC9F-4EF6-913B-69B5F8E5A2BAQ37478602-D0D92089-86FB-496B-A6A5-46D0B6DDC938Q38739564-BBBE2A4A-1419-459F-9843-8BD71E798C96Q39156849-589F8B22-6B13-48C5-961A-B3BCE1E6D8F1Q39782209-51AA264A-C875-445D-B6B4-FF9EA2A600DBQ47113464-96888EF0-6EF2-46F9-B312-0E7600290BF4Q47410522-C4FC270B-68C0-4CD5-A264-895BBD2BE7ACQ57787055-7F5F9534-0990-450C-9F41-DF7F16EF65C3Q57928555-D5E90FE1-A969-433F-B0E1-BAC7A4EE1C42Q58694406-A8CE9BF3-4398-40AA-B0B5-2AFE8D201D9C
P2860
UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
UNBS5162, a novel naphthalimid ...... experimental prostate cancers
@ast
UNBS5162, a novel naphthalimid ...... experimental prostate cancers
@en
type
label
UNBS5162, a novel naphthalimid ...... experimental prostate cancers
@ast
UNBS5162, a novel naphthalimid ...... experimental prostate cancers
@en
prefLabel
UNBS5162, a novel naphthalimid ...... experimental prostate cancers
@ast
UNBS5162, a novel naphthalimid ...... experimental prostate cancers
@en
P2093
P2860
P50
P356
P1433
P1476
UNBS5162, a novel naphthalimid ...... experimental prostate cancers
@en
P2093
Christine Decaestecker
Céline Bruyère
Ellen van der Aar
Eric Van Quaquebeke
Francis Darro
Gentiane Simon
Janique Dewelle
Mischaël J M Dehoux
Nancy De Nève
Robert Kiss
P2860
P304
P356
10.1593/NEO.08290
P577
2008-06-01T00:00:00Z